If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%. That is the pitch for ...

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Fri, April 3, 2026 at 2:17 PM UTC The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund ...

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Biotech has benefited marginally from this rotation. Value beat growth notably in the first quarter. The energy sector was obviously the best performing of the 11 sectors of the S&P 500 in Q1 with a ...

Cathie Wood’s ARK ETF published their daily trades for Monday, April 27th, 2026, revealing significant activity in the biotechnology and aerospace sectors. The largest trade of the day was the sale of ...

Cannabis ETFs entered 2026 after multiple fund closures, stalled federal reform, and a prolonged multi‑year drawdown in underlying equities. The contraction of the product lineup has left a smaller ...

April 13 (Reuters) - Alamar Biosciences and Kailera Therapeutics kicked off roadshows for their U.S. initial public offerings on Monday, aiming for billion-dollar-plus valuations ‌as biotech companies ...